Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus LIQUID E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus LIQUID E Z PAQUE.
DIONOSIL OILY vs LIQUID E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
None Documented
None Documented
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent